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Simple Summary: The efficacy of cancer therapeutics depends on several factors, including the
tumor genome, epigenome, and transcriptome. In addition, the tumor microenvironment, which con-
sists mainly of immune cells, can influence cancer treatment outcomes. Hence, effectively leveraging
host immunity is an important aspect of cancer treatment strategies. The human gut microbiome
is involved in the regulation of the immune responses and affects the efficacy of chemotherapeutic
and immunotherapeutic agents, including oxaliplatin, cyclophosphamide, and immune checkpoint
inhibitors. This study reveals an additional dimension to the Bifidobacterium strain-specific determina-
tion of anti-cancer therapeutic efficacy using flow cytometry and transcriptome analysis of bacterial
strain-fed mice and bacterial whole transcriptome analysis. We hope that our work will contribute to
leveraging the gut microbiome to improve anti-cancer therapies.
Abstract: Colorectal cancer (CRC) is among the leading causes of cancer-related death in the world.
The development of CRC is associated with smoking, diet, and microbial exposure. Previous studies
have shown that dysbiosis of the gut microbiome affects cancer development, because it leads to
inflammation and genotoxicity. Supplementation with specific microbiota induces anti-tumor effects
by enhancing of anti-tumor immunity. Here, we observed that supplementation with either of two
B. breve strains reduces tumor growth in MC38 colon carcinoma-bearing mice. Interestingly, only one
B. breve strain boosted the efficacy of cancer therapeutics, including oxaliplatin and PD-1 blockade.
Extensive immune profiling and transcriptomic analysis revealed that the boosting B. breve strain
augments lymphocyte-mediated anti-cancer immunity. Our results suggest that supplementation
with B. breve strains could potentially be used as a strategy to enhance the efficacy of CRC therapeutics.
Keywords: colorectal cancer; Bifidobacterium breve; oxaliplatin; PD-1 blockade; transcriptomic analysis
1. Introduction
It is increasingly reported that the gut microbiota plays a critical role in host metabolism
and immunity [1], and that the gut microbiome composition changes with age, diet, and
diseases [2,3]. Colorectal cancer (CRC) is among the leading causes of cancer death in men
and women in the United States of America (USA). The development of CRC is related to
genetic and epigenetic alterations, inflammation, and microbial exposure [4–6]. Specific
gut microbiota, such as Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis, and
Escherichia coli are correlated with the development of intestinal adenomas and carcinomas,
because they damage the DNA and affect immune and intestinal barrier functions [7–9].
Several studies have demonstrated that supplementation with gut microbiota species,
including Enterococcus hirae, Lactobacillus johnsonii, and Bifidobacterium species reinforces
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the efficacy of platinum-based chemotherapy, cyclophosphamide, and immunotherapy by
enhancing anti-tumor immune responses [10–12].
Bifidobacterium is the dominant member of the early life gut microbiome, mainly
consisting of B. infantis, B. longum, and B. breve [13–15]. As an important part of the gut
microbiome in infants, Bifidobacterium spp. reduce the risk of intestinal infections, including
neonatal necrotizing enterocolitis, by regulating immune responses and protecting against
intestinal barrier dysfunction [16–18]. Bifidobacterium spp. also affect immunotherapy
responses, and supplementation with Bifidobacterium spp. in a mouse cancer model signifi-
cantly improved anti-tumor immunity by CD8+ T cells [12]. In this study, we identified
B. breve strains that influence cancer growth and the efficacy of cancer therapeutics through
immune activation, and further investigated the underlying genetic mechanisms. Our
results provide important insights regarding the gut microbiome and its applications in
cancer patients.
2. Materials and Methods
2.1. Mice
All animal experiments were performed with approval from the Institutional Animal
Care and Use Committee of CHA University (permission number IACIC180010). Mice
used in this study were maintained and handled according to policies approved by CHA
University. Five-week-old female C57B6/N mice were purchased from the Orient Bio
(Gapyeong, Gyeonggi, Korea). For the tumor mice model, mice were orally administered
Bifidobacterium strains for 14 days (−14 day). Then, mice were implanted with 2× 105 MC38
colon adenocarcinoma cells subcutaneously and treated with 3 mg/kg oxaliplatin (S1224,
Selleckchem, Houston, TX, USA) or 2 mg/kg anti-PD-1 mAb (clone RMP1-14, BioXCell,
USA) intraperitoneally. Syngeneic tumor mice were treated 6 times with anti-PD-1 mAb or
oxaliplatin on days 3, 7, 10, 14, 17, and 21. Tumor size was monitored three times a week
until the study endpoint. Tumor volume was calculated as length × width2 × 0.5.
2.2. Cell Culture
MC38 cells were purchased from Kerafast (Cat# EZH204, Winston-Salem, NC, USA)
and authenticated using DNA fingerprint analysis. All cells were free of mycoplasma
contamination. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, GIBCO)
with 10% fetal bovine serum (FBS, GIBCO) and 100 units/mL penicillin (GIBCO) and
streptomycin (GIBCO). All cells were maintained in a humidified incubator at 37 ◦C in a
5% CO2 atmosphere.
2.3. Bacteria
B. breve JCM92 (B. bre JCM92) were purchased from the Japan Culture Collection of Mi-
croorganisms (JCM). B. breve Bb03 (B. bre Bb03) were purchased from DuPont (Wilmington,
NC USA). To verify bacterial viability, we cultured aliquoted cells on BL (Blood Liver) agar
plates at 37 ◦C in anaerobic conditions (O2 < 1 ppm, 5% CO2, 5% N2) for 48 h and counted
viable colonies (viable cells). For in vivo experiments, each B. breve strain was cultured
in BL medium (Kisanbio, Seoul, Korea) at 37 ◦C in an anaerobic condition (O2 < 1 ppm,
5% CO2, 5% N2) for 48 h. After culture, the bacteria were lyophilized for preservation.
Next, we measured colony forming unit (CFU) counts using a PBS serial dilution method
(CORNING, 21-040-CVR). For each sampling point, an aliquot of culture was diluted to
10−6, 10−7, and 10−8, and 100 µL was spread on BL agar plates. After counting CFUs, each
B. breve strain was divided into daily administration doses and stored at 4 ◦C. Each B. breve
strain was treated at 1 × 109 CFU orally once daily. For bacterial whole transcriptome
analysis, each B. breve strain was harvested in the exponential phase. Then, we cultured
two B. breve strains in BL agar media at 37 ◦C in anaerobic conditions (O2 < 1 ppm, 5% CO2,
5% N2) for 48 h. After colony isolation from the BL agar plate, the colony was cultured in
BL broth media at 37 ◦C for 48 h under anaerobic conditions (O2 < 1 ppm, 5% CO2, 5% N2).
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2.4. Flow Cytometry Analysis
Tissues from experimental mice were obtained at day 15 after tumor cell implantation.
Tumors were dissected into small pieces and transferred into RPMI 1640 media (GIBCO)
supplemented with 2.5 mg/mL collagenase I, 1.5 mg/mL collagenase II, 1 mg/mL collage-
nase IV, 50 µg/mL DNase 1, and 0.25 mg/mL hyaluronidase Type IV-S. The tissues were
incubated at 37 ◦C for 50 min and filtered using a 70 µm cell strainer (BD Bioscience, San
Jose, CA, USA). Spleens were homogenized in RPMI 1640 media, incubated in red blood
cell (RBC) lysis buffer (eBioscience, San Diego, CA, USA) and filtered using a 70 µm cell
strainer. Splenocytes and tumor cells were incubated with anti-mouse CD16/CD32 (BD
Bioscience) for 10 min at 4 ◦C to block the Fc receptor. After evaluating cell viability and
surface staining, fixation/permeabilization buffer solution (BioLegend, San Diego, CA)
was added. Splenocytes and tumor cells were stained with the following mouse antibodies:
anti-CD45 (Biolegend, Cat# 103116), CD3 (Biolegend, Cat# 100218), NK1.1 (Biolegend, Cat#
108708), CD49b (Biolegend, Cat# 108910), CD4 (Biolegend, Cat#100422), CD25 (Biolegend,
Cat#101904), Foxp3 (Invitrogen, Waltham, MA, Cat#17-5773-82), CD44 (Biolegend, Cat#
103008), CD62L (Biolegend, Cat#104412), and CD8a (Biolegend, Cat#100706). Cell acquisi-
tion was performed on a CANTO II flow cytometer (BD Bioscience, Franklin Lakes, NJ,
USA) and data were analyzed using FlowJo software (TreeStar, San Carlos, CA, USA).
2.5. Quantitative PCR (qPCR) Analysis of Tumor Tissue
Total RNA from mice tumors was extracted using an RNeasy Plus Mini Kit (Qiagen, Ger-
mantown, MD) and reverse transcription was conducted using a PrimeScript First Strand cDNA
Synthesis Kit (Takara, Mountain View, CA). qPCR analysis was performed using SYBR Premix Ex
Taq (Tli RNase H Plus) (Takara) and a CFX384 Touch instrument (Bio-Rad, Hercules, CA, USA).
The primers used in this study: IFN-γ, 5′- GAAAGCCTAGAAAGTCTGAATAACT-3′ and 5′-
ATCAGCAGCGACTCCTTTTCCGCTT-3′; IL-2, 5′-ATGTACAGCATGCAGCTCGCATC-3′ and
5′-GGCTTGTTGAGATGATGCTTTGACA-3′; IL-10, 5′-TGAAGACCCTCAGGATGCGG-3′ and
5′-AGAGCTCTGTCTAGGTCCTGG-3′; and β-actin, 5′- CGTGCGTGACATCAAAGAGAA-3′
and 5′-TGGATGCCACAGGATTCCAT-3′. PCR conditions were as follows. For IFN-γ, IL-2,
and β-actin: initial denaturation at 95 ◦C for 1 min; 35 cycles of denaturation (95 ◦C for 30 s),
annealing (60 ◦C for 30 s), and extension (72 ◦C for 1 min), and a final extension at 72 ◦C for
1 min. For IL-10: initial denaturation at 95 ◦C for 1 min, 40 cycles of denaturation (95 ◦C for 30 s),
annealing (60 ◦C for 30 s), and extension (72 ◦C for 1 min); and a final extension at 72 ◦C for
1 min.
2.6. Mice RNA Sequencing and Data Analysis
Intestines were harvested at day 22 after MC38 tumor cell inoculation, and an RNeasy
Mini Kit (Qiagen) was used to extract RNA. After RNA extraction, 151-bp paired-end
libraries were constructed from 1 µg RNA using a TruSeq RNA Sample Prep Kit v2
(Illumina, San Diego, CA). Whole-RNA sequencing was performed on an Illumina HiSeq
instrument. RNA-seq reads were aligned to the mouse reference genome (GRCm38) using
the STAR aligner [19]. Quantification of gene expression and differential expression analysis
were performed using RSEM [20] and the edgeR package [21]. The ClueGO plug-in (v2.5.4,
http://www.ici.upmc.fr/cluego/, 1 January 2009) in Cytoscape software (v3.3.0, http://
cytoscape.org/, 1 January 2003) was used to analyze gene ontology (GO) [22]. Functionally-
related GO terms for biological processes in Mus musculus (version: 27 February 2019) were
grouped based on a kappa score > 0.4 and a network specificity of 5–10 using GO term
fusion. Statistical significance was calculated using a two-sided hypergeometric test, and
the false discovery rate was corrected using the Bonferroni step-down method.
2.7. Bacterial RNA Sequencing and Data Analysis
Bacterial RNA was extracted using the ZymoBIOMICS RNA Miniprep Kit (Zymo
Research, Irvine, CA). Sequencing and library construction were performed on the Illumina
Hiseq 2500 with 101 bp paired-end. Ribosomal RNA was removed using the Ribo-Zero™
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rRNA Removal Kit (Bacteria) (Epicentre, Madison, WI). Libraries were prepared with the
TruSeq RNA Sample Prep kit v2 (Illumina). RNA-sequenced reads were mapped on the
reference genome of Bifidobacterium breve (NZ_AP012324.1) using STAR with alignIntron
MAX 1 [19]. Then, the mapped reads were used to calculate read counts of genes using
cufflinks [23], and the gene list was inputted into Cytoscape plug-in ClueGO v2.5.4 [22]
to annotate functionally grouped networks. Functionally related GO terms for biological
processes in Escherichia coli (version: November 18, 2016) were grouped based on a kappa
score greater than 0.4 with a network specificity of 4–10. Statistical significance was
calculated using two-sided hypergeometric tests, and the false discovery rate was corrected
using the Bonferroni step down method.
2.8. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 8.4.3. Differences between
groups were analyzed using one-way or two-way ANOVA with Tukey’s post-test. Differ-
ences between groups were considered significant if p < 0.05. Statistical details are provided
in the figure legends.
3. Results
3.1. Mice Supplemented with B. breve Strains Exhibit Anti-Tumor Effects
To examine the anti-tumor effects of Bifidobacterium spp. on colon cancer, we adminis-
tered Bifidobacterium strains alone (B. breve JCM1192, B. bre JCM92; B. breve Bb03, B. bre Bb03)
with oxaliplatin to MC38 colon carcinoma-bearing mice (Figure 1A and Table S1). Oral
administration of B. breve in tumor-bearing mice significantly decreased tumor growth,
compared to mice treated with the vehicle (phosphate-buffered saline; PBS) (Figure 1B).
To determine the relationship between B. breve strain supplementation and cancer ther-
apeutics, we treated colon carcinoma-bearing mice with each B. breve strain alone and
in combination with oxaliplatin (Figure 1A). Oxaliplatin is a third-generation platinum-
derivative chemotherapeutic agent and is an important metastatic CRC medication [24,25].
Interestingly, when mice were treated with oxaliplatin and B. breve strains, only mice treated
with B. bre JCM92 showed significantly decreased tumor growth compared to mice treated
with oxaliplatin alone (Figure 1B). To understand why only B. bre JCM92 enhanced the
effect of oxaliplatin, we performed RNA sequencing of B. bre JCM92 (boosting strain) and
B. bre Bb03 (non-boosting strain). We observed that 88 genes were upregulated in B. bre
JCM92 compared to B. bre Bb03 (Table S2, Fold Change > 2). ClueGO analysis showed that
27 terms, including protein processing, intracellular protein transport, cellular amino acid
metabolic process, ribonucleoside metabolic process, and peptide metabolic process were
significantly enriched in B. bre JCM92 (Figure 1C and Table S3).
3.2. B. bre JCM92 Boosts the Efficacy of Oxaliplatin by Enhancing Anti-Tumor Immunity
To investigate the mechanism by which Bifidobacterium strains induce anti-tumor
effects, we performed immune cell profiling of spleen and tumor tissue 15 days after tumor
transplantation. Mice treated with B. bre JCM92 and B. bre Bb03 had increased CD4+ T,
CD8+ T, and effector CD8+ T, and NK cells. These mice also had an increased ratio of
CD4+/regulatory T cells (Tregs), CD8+/Tregs, and effector CD8+/Tregs. However, the
mice had decreased Treg counts in splenocytes (Figure 2A,B). When we compared immune
cell profiling between oxaliplatin alone and oxaliplatin + B. breve-treated groups, B. bre
JCM92 enhanced the effect of oxaliplatin by increasing CD4+ T, CD8+ T, NK cells and the
CD4+/Treg, CD8+/Treg, and effector CD8+/Treg ratios (Figure 2A). However, B. bre Bb03
did not boost the anti-tumor effect of oxaliplatin (Figure 2B).
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Figure 1. Supplementation of Bifidobacterium strains exhibits anti-tumor effects. (A) Experimental 
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continued until the end of the experiment. After tumor inoculation, oxaliplatin or PD-1 blockade 
was injected intraperitoneally. (B) Tumor growth curves after administering Bifidobacterium 
strains, with or without oxaliplatin. Oxp, oxaliplatin; B. bre JCM92, B. breve JCM92; B. bre Bb03, B. 
breve Bb03. Data are expressed as the means ± standard error of means (SEM). p-values were deter-
mined by two-way ANOVA using Tukey’s post-test. (C) Representation of the ClueGO functional 
network analysis of the upregulated genes in B. bre JCM92 compared to B. bre Bb03 (Fold change > 
2).*** p < 0.001, and ns, not significant. 
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Figure 1. Supplementation of Bifidobacterium strains exhibits anti-tumor effects. (A) Experimental
protocol: each Bifidobacterium strain was administered orally 14 days before MC38 inoculation and
continued until the end of the experiment. After tumor inoculation, oxaliplatin or PD-1 blockade was
injected intraperitoneally. (B) Tumor growth curves after administering Bifidobacterium strains, with
or without oxaliplatin. Oxp, oxaliplatin; B. bre JCM92, B. breve JCM92; B. bre Bb03, B. breve Bb03. Data
are expressed as the means ± standard error of means (SEM). p-values were determined by two-way
ANOVA using Tukey’s post-test. (C) Representation of the ClueGO functional network analysis of
the upregulated genes in B. bre JCM92 compared to B. bre Bb03 (Fold change > 2). *** p < 0.001, and
ns, not significant.
Immune cell profiling of tumor-infiltrating lymphocytes (TILs) revealed that B. bre
JCM92 and B. bre Bb03 significantly increased the CD4+/Treg, CD8+/Treg, and the effector
CD8+/Treg ratio (Figure 3A,B). Furthermore, oxaliplatin combined with B. bre JCM92 sig-
nificantly increased CD8+ T cells and the CD4+/Treg and CD8+/Treg ratios (Figure 3A,B).
Next, we examined intra-tumor cytokine expression using qPCR. Interferon-gamma (IFN-
γ) and interleukin-2 (IL-2) expression in tumor tissue was much higher in mice treated
with oxaliplatin with or without B. breve strains (B. bre JCM92 and B. bre Bb03) compared to
IFN-γ and IL-2 expression in vehicle-treated mice. Notably, mice treated with combined
oxaliplatin and B. bre JCM92 exhibited significantly higher IFN-γ and IL-2 expression
than mice treated with oxaliplatin alone (Figure 3C). In contrast, interleukin 10 (IL-10)
expression was much lower in the mice treated with oxaliplatin with or without B. breve
strains than in mice treated with the vehicle (Figure 3C). These results demonstrate that B.
breve monotherapy induces anti-tumor effects by augmenting anti-tumor immunity, but
only B. bre JCM92 enhances the anti-tumor effects of oxaliplatin.
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post-test. * p < 0.05, ** p < 0.001, *** p < 0.001, and ns, not significant. 
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Figure 2. B. bre JCM92 boosts oxalipl tin efficacy by enhancing anti-tu or immunity in the spleen.
(A,B) Immune cell profiling of the spleen in mice treated with oxaliplatin in combination with B. bre
JCM92 (A) or B. bre Bb03 (B) using flow cytometry analysis. Data are expressed as the means ± SEM.
p-values were determined by one-way ANOVA using Tukey’s post-test. * p < 0.05, ** p < 0.001,
*** p < 0.001, and ns, not significant.
3.3. B. bre JCM92 Boosts the Efficacy of PD-1 Blo kade by Enhancing Anti-Tumor Immunity
Several studies have revealed that the gut microbiota enhances the response of im-
mune checkpoi t inhibitors th t target cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed cell death protein-1 (PD-1) [12,26]. Therefore, we tested whether Bifidobac-
terium strains boost the efficacy of PD-1 blockad (Figure 4A). Similar to previous results,
mice treated with a PD-1 blockade and B. bre JCM92 xhib ted significantly decreased
tumor growth compared to mice treated with PD-1 b ockad alone (Figure 4A).
Splenic immune cell profiling showed that combined PD-1 blockade and B. bre JCM9
significantly enhanced anti-tumor immunity by increasing CD8+ T, effector CD8+ T, and
NK cells. Additionally, co bined PD-1 blockade and B. bre JCM92 incre sed the CD8+/Treg
and effector CD8+/Treg ratios compared to PD-1 blockade alone (Figu 4B). In tumor
tissue, PD-1 blockade combined with B. bre JCM92 significantly increased the CD8+ T cell
level and the CD8+/Treg ratio compared to PD-1 blockade alone (Figure 5A). However,
immune cell profiling of the spleen and tumor tissue revealed that B. bre Bb03 did not
enhance the anti-tumor immunity of PD-1 blockade (Figures 4C and 5B). Intra-tumoral
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cytokine expression revealed that mice treated with PD-1 blockade and B. bre JCM92 had
much higher IFN-γ and IL-2 expression compared to mice treated with PD-1 blockade
alone (Figure 5C). Although IFN-γ expression was significantly enhanced in mice treated
with PD-1 blockade combined with B. bre Bb03, the combination of PD-1 blockade and B. bre
JCM92 resulted in higher IFN-γ expression (Figure 5C). IL-10 expression was significantly
decreased in mice treated with PD-1 blockade and either B. breve strain (Figure 5C).




Figure 3. B. bre JCM92 boosts oxaliplatin efficacy by enhancing anti-tumor immunity. (A,B) Im-
mune cell profiling of tumor tissue in mice treated with oxaliplatin in combination with B. bre 
JCM92 (A) or B. bre Bb03 (B) using flow cytometry analysis. Data are expressed as the means ± 
SEM. p-values were determined by one-way ANOVA using Tukey’s post-test. (C) Expression of 
intratumoral cytokines in mice treated with oxaliplatin combined with B. bre JCM92 or B. bre Bb03 
were measured using qPCR. Data are expressed as the means ± SEM. p-values were determined by 
one-way ANOVA using Tukey’s post-test within oxaliplatin treated groups. For all graphs, * p < 
0.05, ** p < 0.01, *** p < 0.001, and ns, not significant. 
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Figure 3. B. bre JCM92 boosts oxaliplatin efficacy by enhancing anti-tumor immunity. (A,B) Immune
cell profiling of tumor tissue in mice treated with oxaliplatin in combination with B. bre JCM92 (A) or
B. bre Bb03 (B) using flow cytometry analysis. Data are expressed as the means ± SEM. p-values were
determined by one-way ANOVA using Tukey’s post-test. (C) Expression of intratumoral cytokines
in mice treated with oxaliplatin combined with B. bre JCM92 or B. bre Bb03 were measured using
qPCR. Data are expressed as the means± SEM. p-values were determined by one-way ANOVA using
Tukey’s post-test within oxaliplatin treated groups. For all graphs, * p < 0.05, ** p < 0.01, *** p < 0.001,
and ns, not significant.




Figure 4. B. bre JCM92 boosted PD-1 blockade efficacy. (A) Tumor growth curves after administer-
ing B. breve strains, with or without PD-1 blockade. Data are expressed as the means ± SEM. p-
values were determined by two-way ANOVA using Tukey’s post-test. (B,C) Immune cell profiling 
of spleen tissue in mice treated with PD-1 blockade in combination with B. bre JCM92 (B) or B. bre 
Bb03 (C) using flow cytometry analysis. Data are expressed as the means ± SEM. p-values were 
determined by one-way ANOVA using Tukey’s post-test. For all graphs, * p < 0.05, ** p < 0.01, *** p 
< 0.001, and ns, not significant. 
Splenic immune cell profiling showed that combined PD-1 blockade and B. bre JCM92 
significantly enhanced anti-tumor immunity by increasing CD8+ T, effector CD8+ T, and 
NK cells. Additionally, combined PD-1 blockade and B. bre JCM92 increased the 
CD8+/Treg and effector CD8+/Treg ratios compared to PD-1 blockade alone (Figure 4B). In 
tumor tissue, PD-1 blockade combined with B. bre JCM92 significantly increased the CD8+ 
T cell level and the CD8+/Treg ratio compared to PD-1 blockade alone (Figure 5A). How-
ever, immune cell profiling of the spleen and tumor tissue revealed that B. bre Bb03 did 
not enhance the anti-tumor immunity of PD-1 blockade (Figure 4C and Figure 5B). Intra-
tumoral cytokine expression revealed that mice treated with PD-1 blockade and B. bre 


























































































































































































































































































































































































































































































Fig re 4. . bre J 92 boosted PD-1 blockade efficacy. (A) Tumor growth curves after administering
B. breve strains, with or without PD-1 blockade. Data are expressed as the means ± SEM. p-values
were determined by two-way ANOVA using Tukey’s post-test. (B,C) Immune cell profiling of
spleen tissue in mice treated with PD-1 blockade in combination with B. bre JCM92 (B) or B. bre
Bb03 (C) using flow cytometry analysis. Data are expressed as the means ± SEM. p-values were
determined by one-way ANOVA using Tukey’s post-test. For all graphs, * p < 0.05, ** p < 0.01,
*** p < 0.001, and ns, not significant.
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Figure 5. B. bre JCM92 boosts PD-1 blockade efficacy by enhancing anti-tumor immunity in tumor
tissue. (A,B) Immune cell profiling of tumor in mice treated with PD-1 blockade in combination with
B. bre JCM92 (A) or B. bre Bb03 (B) using flow cytometry analysis. (C) Expression of intra-tumoral
cytokines in mice treated with PD-1 blockade in combination with B. bre JCM92 or B. bre Bb03
were m asur d sing qPCR. Data are expressed as the means ± SEM. p-values were d termined
by one-way ANOV using T key’s post-test within the PD-1 blockade-treat d groups. * p < 0.05,
** p < 0.01, *** p < 0.001, and ns, not significant.
3.4. Transcriptome Analysis of Intestinal Tissue Reveals That B. bre JCM92 Has the Ability to
Boost the Effects of Cancer Therapeutics
To understand the mechanism by which the administration of the gut microbiome
influences the intestine and anti-tumor immune responses, we performed whole transcrip-
tome sequencing on the intestine of mice treated with cancer therapeutics and B. bre JCM92
and B. bre Bb03. Hierarchical clustering analysis revealed that intestinal gene-expression
patterns were distinct between mice treated with B. bre JCM92 and B. bre Bb03 (Figure 6A).
We analyzed differentially expressed genes (DEGs) between the enhanced (oxaliplatin +
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B. bre JCM92 and PD-1 blockade + B. bre JCM92) and unenhanced groups (oxaliplatin +
B. bre Bb03 and PD-1 blockade + B. bre Bb03; p < 0.001; Figure 6B). Cytoscape network
visualization exhibited that DEGs from mice treated with cancer therapeutics and B. breve
strains (B. bre JCM92 and B. bre Bb03) are biologically related (Figure 6C). ClueGO anal-
ysis revealed that the term “Regulation of cytokines” was significantly enriched in mice
treated with cancer therapeutics combined with B. bre JCM92 compared to mice treated
with cancer therapeutics and B. bre Bb03 (Figure 6D and Table S4). Next, we performed
gene set enrichment analysis (GSEA) between the boosted group and non-boosted group.
The significantly enriched gene signatures in mice treated with the cancer therapeutics
(oxaliplatin and PD-1 blockade) and B. bre JCM92 compared to mice treated with cancer
therapeutics and B. bre Bb03 included gene sets involving E2F targets, tumor necrosis
factor-α (TNF-α) signaling via nuclear factor kappa B (NFκB), allograft rejection, and
inflammatory response (Figure 6E and Figure S1). Consistent with tumor cytokine expres-
sion, mice treated with cancer therapeutics and B. bre JCM92 exhibited higher IL-2, STAT5
signaling, and IFN-γ response compared to mice treated with oxaliplatin or PD-1 blockade
and B. bre Bb03 (Figure 6F and Figure S2). Transcription factors regulate transcription
initiation by recognizing specific binding sites, and transcription factor dysregulation is
associated with human cancers [27–29]. To understand the regulatory mechanism of the
gut microbiome, motif analysis of the intestinal transcriptome was performed. Nuclear
transcription factor Y subunit beta and nuclear transcription factor Y subunit alpha genes
were significantly associated with the upregulated genes in mice treated with the combina-
tion of cancer therapeutics and B. bre JCM92 (boosted group; Figure 6G). Nuclear factor
Y binds to the interleukin-4 (IL-4) promoter and regulates IL-4 gene expression [30,31].
IL-4 regulates lymphocyte expansion and function [32] and exhibits anti-tumor activity
by promoting Gr-1+ granulocyte and CD8+ T cell maturation [33]. These results reveal
that supplementation of B. breve affects intestinal gene expression and that the changes are
associated with anti-tumor immune responses.
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Figure 6. Effect of cancer therapeutics and B. breve strains on the intestinal transcriptome. (A) Heat map showing hierarchical
clustering of differentially expressed genes (DEGs) between mice treated with cancer therapeutics (oxaliplatin or PD-1
blockade) and B. bre JCM92 or B. bre Bb03. (B) Volcano plots illustrating genes between mice treated with cancer therapeutics
and B. bre JCM92 and mice treated with cancer therapeutics and B. bre Bb03. Red dots represent significantly different genes
(p < 0.001). (C) Network analysis of DEGs from mice treat d with can er therapeutics and B. bre JCM92, and mice reated
with cancer therapeutics and B. bre Bb03 using Cytoscape. Co-expressed and co-localized genes are indicated by purple
and blue lines, respectively. (D) Representation of the ClueGO functional network analysis shows upregulated genes in
mice treated with cancer therapeutics and B. bre JCM92 compared to mice treated with cancer therapeutics and B. bre Bb03.
(E,F) GSEA of intestinal transcriptome data exhibited that mice treated with cancer therapeutics and B. bre JCM92 were
significantly enriched in hallmark pathways compared to mice treated with cancer therapeutics and B. bre Bb03. (G) Motifs
within upregulated genes of mice treated with cancer therapeutics and B. bre JCM92. NFYB, nuclear transcription factor Y
subunit beta; NFYA, nuclear transcription factor Y subunit alpha.
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4. Discussion
The gut microbiome affects immune system development and differentiation by regu-
lating innate immune responses, including innate lymphoid cells and gene expression [34].
Several diseases, such as cancer, obesity, and inflammatory bowel diseases are correlated
with intestinal dysbiosis [34,35]. Previous studies suggest that supplementation with
probiotics influences host homeostasis and has a therapeutic effect on immune-mediated
diseases [36,37]. Bifidobacterium spp. are among the most frequently used as probiotics and
have favorable effects in several diseases, including ulcerative colitis and enteropathogenic
E. coli O157 infection [38,39].
Here, we found that Bifidobacterium strains confer anti-tumor properties. Although
two B. breve strains increased anti-tumor immunity, only one B. breve strain boosted cancer
therapeutic efficacy. Immune cell profiling of spleen and tumor tissue revealed that B. breve
strains alone augmented anti-tumor immunity by increasing CD8+ T and effector CD8+ T
cell numbers, and by increasing the CD8+/Treg and effector CD8+/Treg ratio. However,
only B. bre JCM92 boosted the efficacy of cancer therapeutics.
Interestingly, immune cell profiling exhibited that spleens from mice treated with B. bre
JCM92 and PD-1 blockade had significantly increased CD4+ and CD8+ T cells compared
to PD-1 monotherapy (Figure 4B), whereas tumors from mice treated with B. bre JCM92
and PD-1 blockade only showed enhanced CD8+ T cells compared to PD-1 monotherapy
(Figure 5A). We hypothesize that the CD4+ T cells activate CD8+ cells rather than directly
killing tumor cells. Most CD4+ T cells could not recognize cancer cells directly due to a
lack of MHCII (Major Histocompatibility complex II) in most solid cancer cells (except
melanoma and breast cancer [40]), whereas CD4+ and CD8+ T cells are activated in spleens
under immune activation and inflammatory conditions [41]. For those reasons, increased
CD4+ and CD8+ T were observed from splenocytes analysis, while only CD8+ T cells were
increased in the tumor environment.
Using bacterial transcriptome analysis, we observed that the boosting B. bre JCM92 ex-
pressed genes were significantly enriched in the ribonucleoside metabolic process, cellular
amino acid metabolic process, and amino sugar biosynthetic process pathways compared
to non-boosting B. bre Bb03. Previous studies showed that amino acid degrading enzymes
have anti-tumor effects in preclinical and clinical trials [36,37]. The difference in gene
expression between the two B. breve strains may be related to the boosting effects of B. bre
JCM92. However, the exact anti-cancer molecular mechanisms and metabolic processes
in B. bre JCM92 need to be further investigated. When bacteria are orally administered,
the intestine is the primary colonization site [42,43]. Previous studies also showed that the
gut microbiome composition is an important factor in determining the response to cancer
therapeutics, especially immunotherapy. For instance, Bifidobacterium spp., Ruminococ-
caceae and Faecalibacterium are significantly enriched in melanoma patients who respond to
anti-PD-1 treatment [44,45]. In addition, Akkermansia muciniphila abundance is associated
with anti-PD-1 treatment response in epithelial tumors [46]. Therefore, we hypothesize
that the boosting effects of B. breve appear by altering intestinal gene expression. Intesti-
nal transcriptome analysis showed that mice treated with cancer therapeutics and B. bre
JCM92 showed significantly enriched E2F targets, TNF-α signaling via NFκB, inflammatory
responses, and IFN-γ responses. The E2F family of transcription factors plays an impor-
tant role as transcriptional regulators of cell cycle-dependent gene expression [47], and
also modulate apoptosis, metabolism, and angiogenesis in cancer [48,49]. E2F expression
in cancer shows conflicting results in both tumor suppression and progression [50,51].
However, the relationship between E2F expression in the intestine and tumors has not
yet been investigated. TNF-α is produced by various cells, including macrophages, NK
cells, and T cells, and is released in response to peptidoglycan, lipopolysaccharide, and
bacterial components [52,53]. Furthermore, TNF-α is involved in apoptosis, cell survival,
and inflammation, and is a potential target for cancer therapy [52,54]. Previous studies
have shown that TNF-α enhances antitumor effects when used in combination with other
cancer therapeutics and cytokines, including adriamycin, actinomycin D, and IFN-γ [55,56].
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Similarly to the intestinal transcriptome analysis, intra-tumoral IFN-γ expression was
significantly enhanced in mice treated with B. bre JCM92 (boosting) and cancer therapeutics
compared to mice treated with B. bre Bb03 (non-boosting) and cancer therapeutics. IFN-γ is
a major player in anti-tumor immunity, and exerts anti-proliferative and pro-apoptotic ef-
fects in tumor cells [57–60], recruits immune cells into the tumor microenvironment [61,62],
and enhances the tumoricidal activities of innate and adaptive immune cells [63–65]. This
cytokine also exhibits anti-angiogenic activity via its anti-proliferative and apoptotic ef-
fects on endothelial cells [66,67]. Mutations in IFN-γ signaling genes were identified in
tumors resistant to cancer immunotherapy, highlighting the essential role for this protein
in chemotherapy responses [68,69]. These results demonstrate that the administration of B.
bre JCM92 increases anti-tumor immunity by modulating cytokines, including TNF-α and
IFN-γ, through the gut–systemic–tumor pathway. However, IL-10 expression was different
between intestine and tumors. This difference demonstrates that the anti-tumor effects of
B. breve are not same in all tissues. We hypothesize that other molecules, including metabo-
lites, underlie these differences. Investigating the underlying mechanisms distinguishing
intestine and tumor tissue after B. breve treatment needs to be further explored.
5. Conclusions
In summary, we identified two B. breve strains that show anti-tumor effects by enhanc-
ing anti-tumor immunity. Notably, only specific Bifidobacterium strains boosted the efficacy
of cancer therapeutics. Further study is needed to examine whether supplementation with
Bifidobacterium strains can be used as supportive anti-tumor drugs to boost the efficacy of
cancer therapeutics in clinical trials.
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